Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Postprandial hypertriglyceridemia and cardiovascular disease: current and future therapies.

Chan DC, Pang J, Romic G, Watts GF.

Curr Atheroscler Rep. 2013 Mar;15(3):309. doi: 10.1007/s11883-013-0309-9. Review.

PMID:
23345190
2.

Recent advances in pharmacotherapy for hypertriglyceridemia.

Sahebkar A, Chew GT, Watts GF.

Prog Lipid Res. 2014 Oct;56:47-66. doi: 10.1016/j.plipres.2014.07.002. Epub 2014 Jul 30. Review.

PMID:
25083925
3.

Postprandial hypertriglyceridemia as a coronary risk factor.

Borén J, Matikainen N, Adiels M, Taskinen MR.

Clin Chim Acta. 2014 Apr 20;431:131-42. doi: 10.1016/j.cca.2014.01.015. Epub 2014 Feb 6. Review.

PMID:
24508990
4.

Postprandial lipemia as a cardiometabolic risk factor.

Pirillo A, Norata GD, Catapano AL.

Curr Med Res Opin. 2014 Aug;30(8):1489-503. doi: 10.1185/03007995.2014.909394. Epub 2014 May 2. Review.

PMID:
24673475
5.

Demystifying the management of hypertriglyceridaemia.

Watts GF, Ooi EM, Chan DC.

Nat Rev Cardiol. 2013 Nov;10(11):648-61. doi: 10.1038/nrcardio.2013.140. Epub 2013 Sep 24. Review.

PMID:
24060958
6.

Optimal management of combined dyslipidemia: what have we behind statins monotherapy?

Tenenbaum A, Fisman EZ, Motro M, Adler Y.

Adv Cardiol. 2008;45:127-53. doi: 10.1159/0000115192. Review.

PMID:
18230960
7.
8.

Statins and diabetes.

Carmena R, Betteridge DJ.

Semin Vasc Med. 2004 Nov;4(4):321-32. Review.

PMID:
15861314
9.

Therapeutic effects of fibrates in postprandial lipemia.

Kolovou GD, Kostakou PM, Anagnostopoulou KK, Cokkinos DV.

Am J Cardiovasc Drugs. 2008;8(4):243-55. Review.

PMID:
18690758
10.

Postprandial lipemia--effect of lipid-lowering drugs.

Karpe F.

Atheroscler Suppl. 2002 May;3(1):41-6. Review.

PMID:
12044585
11.

Emerging approaches for the treatment of hypertriglyceridemia.

Rizzo M, Perez-Martinez P, Nikolic D, Montalto G, Lopez-Miranda J.

Expert Opin Pharmacother. 2013 Oct;14(14):1869-73. doi: 10.1517/14656566.2013.823402. Epub 2013 Sep 6.

PMID:
24011268
12.

Evidence for impaired lipolysis in abdominally obese men: postprandial study of apolipoprotein B-48- and B-100-containing lipoproteins.

Couillard C, Bergeron N, Pascot A, Alméras N, Bergeron J, Tremblay A, Prud'homme D, Després JP.

Am J Clin Nutr. 2002 Aug;76(2):311-8.

13.

Hypertriglyceridemia and cardiovascular risk reduction.

Jacobson TA, Miller M, Schaefer EJ.

Clin Ther. 2007 May;29(5):763-77. Review.

PMID:
17697898
14.

An ABC of apolipoprotein C-III: a clinically useful new cardiovascular risk factor?

Chan DC, Chen MM, Ooi EM, Watts GF.

Int J Clin Pract. 2008 May;62(5):799-809. doi: 10.1111/j.1742-1241.2007.01678.x. Epub 2008 Jan 14. Review.

PMID:
18201179
15.

Novel therapeutics in hypertriglyceridemia.

Gryn SE, Hegele RA.

Curr Opin Lipidol. 2015 Dec;26(6):484-91. doi: 10.1097/MOL.0000000000000231. Review.

PMID:
26780002
16.

Why, when and how should hypertriglyceridemia be treated in the high-risk cardiovascular patient?

Watts GF, Karpe F.

Expert Rev Cardiovasc Ther. 2011 Aug;9(8):987-97. doi: 10.1586/erc.11.61. Review.

PMID:
21878044
17.

A physician's guide for the management of hypertriglyceridemia: the etiology of hypertriglyceridemia determines treatment strategy.

Klop B, Wouter Jukema J, Rabelink TJ, Castro Cabezas M.

Panminerva Med. 2012 Jun;54(2):91-103. Review.

PMID:
22525564
19.

Effect of atorvastatin on postprandial lipoprotein metabolism in hypertriglyceridemic patients.

Parhofer KG, Laubach E, Barrett PH.

J Lipid Res. 2003 Jun;44(6):1192-8. Epub 2003 Apr 1.

20.

Postprandial dyslipidaemia and diabetes: mechanistic and therapeutic aspects.

Pang J, Chan DC, Barrett PH, Watts GF.

Curr Opin Lipidol. 2012 Aug;23(4):303-9. doi: 10.1097/MOL.0b013e328354c790. Review.

PMID:
22595742

Supplemental Content

Support Center